Search results for "Plate"

showing 10 items of 1689 documents

Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial

2020

AbstractPatients with stroke or transient ischemic attacks (TIAs) and internal carotid artery stenosis harbor an increased risk of recurrent stroke especially within 2 weeks after the first event. In addition, the revascularization procedure itself (carotid endarterectomy [CEA] or carotid artery stenting [CAS]) is associated with both clinically apparent and silent brain infarctions, mainly caused by the embolic nature of the ruptured carotid plaque. The glycoprotein VI (GPVI) fusion protein Revacept is a highly specific antithrombotic drug without direct inhibition of systemic platelet function that might reduce periprocedural distal embolization from the vulnerable ruptured plaque located…

medicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_treatmentCarotid endarterectomy030204 cardiovascular system & hematologyplatelet inhibitorRevascularization03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arteryAntithromboticmedicineMyocardial infarctioncardiovascular diseasesStroke030304 developmental biologyrevacept0303 health sciencesbusiness.industrymedicine.diseasestrokeTolerabilitylcsh:RC666-701Hemostasistransient ischemic attackCardiologycarotid stenosisOriginal ArticleInternal carotid arterybusinessTH Open
researchProduct

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.

2018

OBJECTIVE To determine the current state of knowledge and provide evidence-based recommendations that could be valid for all specialists taking care of female pattern hair loss (FPHL), a common form of hair loss in women that is characterized by the reduction of hair density in the central area of the scalp, whereas the frontal hairline is generally well conserved. PARTICIPANTS An expert task force appointed by the Androgen Excess and PCOS Society, which included specialists from dermatology, endocrinology, and reproductive endocrinology. DESIGN Levels of evidence were assessed and graded from A to D. Peer-reviewed studies evaluating FPHL published through December 2017 were reviewed. Crite…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismVasodilator AgentsClinical BiochemistryReproductive EndocrinologySpironolactoneAndrogen ExcessBiochemistry030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineEndocrinology5-alpha Reductase InhibitorsInternal medicinemedicineVitamin D and neurologyHumansLow-Level Light TherapyMineralocorticoid Receptor Antagonists030219 obstetrics & reproductive medicineScalpintegumentary systembusiness.industryPlatelet-Rich PlasmaBiochemistry (medical)HyperandrogenismAlopeciaAndrogen Antagonistsmedicine.diseaseAndrogenDermatologymedicine.anatomical_structureEndocrinologyHair lossMinoxidilScalpMinoxidilFemalebusinessHyperandrogenismmedicine.drugPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

2020

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who hav…

medicine.medical_specialtymedicine.drug_classantithrombotic therapyCoronavirus disease 2019; SARS-CoV-2; anticoagulant; antiplatelet; antithrombotic therapy; thrombosisDisease030204 cardiovascular system & hematologyantiplateletPathogenesis03 medical and health sciences0302 clinical medicineAntithromboticEpidemiologyMedicine030212 general & internal medicinePlatelet activationEndothelial dysfunctionIntensive care medicinethrombosisCoronavirus disease 2019SARS-CoV-2business.industryanticoagulantAnticoagulantmedicine.diseaseThrombosisCardiology and Cardiovascular MedicinebusinessJournal of the American College of Cardiology
researchProduct

2020

Background. Anticoagulant therapy, the cornerstone treatment in acute venous thromboembolism (VTE), strongly impacts thrombin generation (TG). Until now, the appearance of the TG curve in platelet rich plasma (PRP) from patients with acute VTE has not been investigated. Methods. We analyzed the shape of TG curves measured in PARP of 180 acute VTE patients. Results. Normal shape of TG curves was observed in 110 patients, 50 patients showed no TG and 20 patients showed biphasic TG curve. The linear regression analysis, adjusted for age, sex, VTE clinical phenotypes and therapy showed that the appearance of biphasic curves is significantly associated with female sex, presence of cancer and the…

medicine.medical_specialtymedicine.drug_mechanism_of_actionbusiness.industryFactor Xa InhibitorCancerGeneral Medicinemedicine.diseaseGastroenterologyThrombin generationPlatelet-rich plasmaInternal medicinemedicineClinical significanceCurve shapePlateletcardiovascular diseasesbusinessVenous thromboembolismJournal of Clinical Medicine
researchProduct

Role of insulin-like growth factors in autocrine growth of human retinoblastoma Y79 cells.

1996

In this study, we have demonstrated that human retinoblastoma Y79 cells produce insulin-like growth factors (IGFs) type I and type II and release them into the medium. We have also ascertained, by means of competitive studies and cross-linking procedure, that Y79 cells contain the type-I IGF receptor (IGF-IR). Furthermore, surface-bound IGF-I is internalised by the receptor, then degraded to amino acids. Insulin, IGF-I and IGF-II caused down-regulation of IGF-IR; the effect is concentration and time dependant. Scatchard analysis demonstrated that incubation with insulin markedly decreased the binding capacity measured for IGF-I while the apparent Kd value calculated for IGF-I binding was no…

medicine.medical_specialtymedicine.medical_treatmentBiologyBiochemistryBinding CompetitiveReceptor IGF Type 1chemistry.chemical_compoundInsulin-Like Growth Factor IIInternal medicineInsulin receptor substratemedicineHumansInsulinInsulin-Like Growth Factor IAutocrine signallingPhosphotyrosineInsulin-like growth factor 1 receptorInsulinRetinoblastomaTyrosine phosphorylationPhosphoproteinsIRS2Insulin receptorautocrine growthEndocrinologychemistrybiology.proteinInsulin Receptor Substrate ProteinsPlatelet-derived growth factor receptorCell DivisionSignal TransductionEuropean journal of biochemistry
researchProduct

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the G…

2018

Abstract Introduction Thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Underlying mechanisms are poorly known and usually multifactorial. Its treatment is not well defined, mostly based in platelet transfusion. Thus, is important to identify new strategies to manage this important post-SCT complication. Romiplostim and Eltrombopag are currently available thrombopoietin receptor agonists (TPO-RAs) that stimulate platelet production. Some studies with very small number of cases have reported their potential efficacy in the allo-SCT setting. For this reason, the aim of our study is to analyze the efficacy and safety of TPO-RAs for s…

medicine.medical_specialtymedicine.medical_treatmentImmunologyEltrombopagHematopoietic stem cell transplantationNeutropeniaBiochemistryGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicinePlateletRomiplostimbusiness.industryCell BiologyHematologymedicine.diseaseTransplantationPlatelet transfusionGraft-versus-host diseasechemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drugBlood
researchProduct

The EHA research roadmap

2021

International audience; In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research(1) aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1-2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published…

medicine.medical_specialtymedicine.medical_treatmentPlatelet disorderClinical scienceHematopoietic stem cell transplantation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinemedicineDiseases of the blood and blood-forming organsIntensive care medicine030304 developmental biology0303 health sciencesHematologybusiness.industryTransfusion medicineHematologyHemostatic Disorders3. Good healthBlood DisorderEuropean policy[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologiePerspective[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieRC633-647.5businessHemaSphere
researchProduct

Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population

2020

Platelet aggregation inhibitors (PAI) have widely proven their efficiency for the prevention of ischemic cardiovascular events. We aimed to describe PAI prescription in an elderly multimorbid population and to determine the factors that influence their prescription, including the impact of age, comorbidities and frailty, evaluated through a comprehensive geriatric assessment. This cross-sectional study included all patients admitted to the acute geriatric department of a university hospital from November 2016 to January 2017. We included 304 consecutive hospitalized patients aged 88.7 &plusmn

medicine.medical_specialtymultimorbidityHealth Toxicology and MutagenesisFrail ElderlyPopulationlcsh:MedicineunderuseDiseasefrailty030204 cardiovascular system & hematologyoveruseelderlyArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansMedical history030212 general & internal medicineMedical prescriptionPractice Patterns Physicians'educationplatelet aggregation inhibitorsGeriatric AssessmentAgedAged 80 and overeducation.field_of_studyMini–Mental State Examinationmedicine.diagnostic_test[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologybusiness.industry[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologylcsh:RPublic Health Environmental and Occupational HealthOdds ratiocomprehensive geriatric assessmentConfidence intervalCross-Sectional StudiesagePlatelet aggregation inhibitorFemaleantiplatelet agentsbusinessInternational Journal of Environmental Research and Public Health
researchProduct

Variation of platelet function in clinical phenotypes of acute venous thromboembolism – Results from the GMP‐VTE project

2022

Background The role of platelets in the pathogenesis of venous thromboembolism (VTE) is receiving increasing attention; however, limited information is available on platelet function in the acute phase of the disease. Objective To characterize platelet function according to VTE phenotypes. Patients/Methods In total, 154 subjects (isolated pulmonary embolism [iPE], n = 28; isolated deep vein thrombosis [iDVT], n = 35; DVT+PE, n = 91) were included. In this study platelet function analyzer (PFA)-200, light transmission aggregometry (LTA), thrombin generation (TG) in presence (PRP) and absence (PFP) of platelets and platelet flow cytometry were investigated. LASSO regression was used to select…

medicine.medical_specialtypulmonary embolismPlatelet Function TestsPULMONARY-EMBOLISMplatelet functionDeep veinvenous thromboembolism610 MedizinDETERMINANTSGastroenterologydeep vein thrombosisDISEASEPathogenesischemistry.chemical_compoundPlatelet degranulationRISK-FACTOR610 Medical sciencesInternal medicineHumansMedicinePlateletcardiovascular diseasesPOPULATIONVenous Thrombosisbusiness.industryHematologymedicine.diseaseABSENCEThrombosisPREDICTSPulmonary embolismASPIRINAdenosine diphosphatePhenotypeEpinephrinemedicine.anatomical_structurechemistrythrombin generationVOLUMEbusinessmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Sinus floor elevation with platelet-rich fibrin alone : a clinical retrospective study of 1-7 years

2018

Background Several sinus floor elevation procedures for implant placement have been introduced. The present study aimed to evaluate the implants placed with Platelet-rich fibrin (PRF) alone in atrophic posterior maxillae and survival rates and the potential factors associated with implant loss. Material and Methods This retrospective study evaluated 71 implants in 34 patients after 1-7 years' follow-up time. Statistical models were used to determine the implant survival and the potential factors associated with loss. Results Overall, 7 implants were lost, and the cumulative survival rate at 7 years by implant-based and patient-bases analyses were 85.5% and 85.7%, respectively. The mean resi…

medicine.medical_treatmentDentistry02 engineering and technologyFibrin03 medical and health sciences0302 clinical medicineMedicineDental implantGeneral DentistrySurvival rateSinus (anatomy)biologybusiness.industryResearchRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]021001 nanoscience & nanotechnologyPlatelet-rich fibrinmedicine.anatomical_structureMaxillaUNESCO::CIENCIAS MÉDICASbiology.proteinImplantOral Surgery0210 nano-technologybusiness
researchProduct